{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:32:13Z","timestamp":1778250733121,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014384","name":"Amarin Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014384","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005481","name":"School of Medicine, New York University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.ahj.2014.04.001","type":"journal-article","created":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T06:47:06Z","timestamp":1397371626000},"page":"68-75.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial"],"prefix":"10.1016","volume":"168","clinical-trial-number":[{"clinical-trial-number":"nct00391872","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Anna","family":"Kotsia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil S.","family":"Brilakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes","family":"Held","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel P.","family":"Steg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Cools","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc J.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H.","family":"Cornel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Aylward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basil S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Brandrup-Wognsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna R.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Himmelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan K.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2014.04.001_bb0005","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/CIRCULATIONAHA.109.877092","article-title":"Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program","volume":"120","author":"Brilakis","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.04.001_bb0010","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non\u2013ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.04.001_bb0015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.04.001_bb0020","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.04.001_bb0025","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","article-title":"Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"157","author":"James","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.04.001_bb0030","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ahj.2013.06.019","article-title":"Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial","volume":"166","author":"Brilakis","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.04.001_bb0035","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","article-title":"Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study)","volume":"31","author":"Fox","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.04.001_bb0040","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.04.001_bb0045","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.amjcard.2009.04.051","article-title":"Effectiveness of myocardial perfusion scintigraphy to predict coronary anatomy in patients with non\u2013ST elevation acute coronary syndrome","volume":"104","author":"Potter","year":"2009","journal-title":"Am J Cardiol"},{"issue":"9180","key":"10.1016\/j.ahj.2014.04.001_bb0050","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0140-6736(99)07350-X","article-title":"Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.04.001_bb0055","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.04.001_bb0060","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/eurheartj\/ehm194","article-title":"Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach","volume":"28","author":"Nikolsky","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.04.001_bb0065","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.04.001_bb0070","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/heartjnl-2011-301596","article-title":"Prevalence and non-invasive predictors of left main or three-vessel coronary disease: evidence from a collaborative international nmeta-analysis including 22 740 patients","volume":"98","author":"D'Ascenzo","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2014.04.001_bb0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1161\/01.CIR.64.2.360","article-title":"Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS)","volume":"64","author":"Chaitman","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.04.001_bb0080","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2005.01.041","article-title":"Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score","volume":"45","author":"Halkin","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.04.001_bb0085","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa0804626","article-title":"Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease","volume":"360","author":"Serruys","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.04.001_bb0090","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.04.001_bb0095","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/j.ijcard.2013.03.020","article-title":"Treatment and outcomes of non\u2013ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease","volume":"168","author":"Mohareb","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2014.04.001_bb0100","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/CIRCULATIONAHA.107.694273","article-title":"Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?","volume":"116","author":"Spencer","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.04.001_bb0105","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0002-9149(01)02082-3","article-title":"Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non\u2013ST-segment elevation acute myocardial infarction","volume":"88","author":"Berkowitz","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.04.001_bb0110","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.04.001_bb0115","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.111.082727","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack","volume":"125","author":"James","year":"2012","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314002105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314002105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:55:51Z","timestamp":1762077351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870314002105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0002870314002105"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2014.04.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2014.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}